bioAffinity Technologies, UT Health Science Center San Antonio Announce Collaboration to Advance Non-Invasive Cancer Diagnostic

Download as PDF

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, a privately held cancer diagnostics company, today announced the renewal of its research collaboration with The University of Texas Health Science Center at San Antonio to optimize its patented CyPath® test that preferentially binds to cancer cells and causes them to fluoresce red under specific frequencies of light for detection in bodily fluids. The announcement marks the third year of collaboration.

Research is led by Principal Investigator Vivienne Rebel, M.D., Ph.D., a cancer stem cell biologist who received the UT Health Science Center 2012 Cancer Therapy & Research Center Discovery of the Year Award. Her work in the molecular nature of cancer and stem cell biology includes research at the Dana-Farber Cancer Institute, Harvard Medical School in Boston, MA.

“bioAffinity Technologies continues to significantly benefit from its association with the Health Science Center, particularly the team of scientists led by Dr. Rebel who are working with our Company researchers to advance our breakthrough cancer diagnostic,” said Maria Zannes, President and Chief Executive Officer. “We look forward to another year of discovery that translates into accurate, easy-to-use, non-invasive tests to detect cancer at the earliest stages.”

The Company recently announced publication of clinical study results for its non-invasive and quantitative assay for early-stage lung cancer in the September 2015 issue of the Journal of Thoracic Oncology. The porphyrin-based assay had an overall accuracy of 81% in the test population with a false-positive rate of 40% and negative predictive value of 83%.

Optimization research conducted in collaboration with the Health Science Center after completion of the clinical trial is expected to increase all measures of the test’s accuracy, including the sensitivity and specificity of CyPath® to detect lung cancer. Ms. Zannes said ongoing optimization research also has led to greater understanding of the biological mechanism behind CyPath®’s affinity to bind with cancer cells.

About bioAffinity Technologies

bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company advancing proprietary screening and early‐stage diagnostic technology applicable to a broad range of cancers. The Company holds extensive U.S. and international patents that allow for global commercialization of its technology.

bioAffinity Technologies, Inc.
Maria Zannes, 505-400-9747

Source: bioAffinity Technologies, Inc.

Released September 30, 2015